$INCY News

Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target

Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years

Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?

Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong

European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)

Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis

Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Guggenheim Maintains Buy on Incyte, Raises Price Target to $150

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130

Barclays Maintains Overweight on Incyte, Raises Price Target to $139

HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150

Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients

Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Incyte Says It's No Longer A One-Drug Story

Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation

Incyte Q2 Earnings Call Highlights